InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Change in substantial holding 22 Feb 2022 6:14PM $1.025 $0.013 fallen by 98.73%
$18 Change in substantial holding 21 Feb 2022 8:15AM $1.050 $0.013 fallen by 98.76%
$18 Becoming a substantial holder 18 Feb 2022 8:11AM $1.030 $0.013 fallen by 98.74%
$18 Change in substantial holding 16 Feb 2022 8:09AM $1.030 $0.013 fallen by 98.74%
$18 Angiogenesis 2022 -Prof Cheung presentation of PCV data 14 Feb 2022 8:55AM $1.105 $0.013 fallen by 98.82%
$18 Opthea data for OPT-302 in patients with PVC as presented 14 Feb 2022 8:25AM $1.105 $0.013 fallen by 98.82%
$18 Opthea present at SVB Leerink Global Healthcare Conference 11 Feb 2022 8:21AM $1.150 $0.013 fallen by 98.87%
$18 Opthea presents at the Angiogenesis 2022 Conference 10 Feb 2022 8:24AM $1.160 $0.013 fallen by 98.88%
$18 Change in substantial holding 9 Feb 2022 8:18AM $1.110 $0.013 fallen by 98.83%
$18 Change in substantial holding 7 Feb 2022 8:08PM $1.080 $0.013 fallen by 98.80%
$18 Change in substantial holding 4 Feb 2022 6:14PM $1.075 $0.013 fallen by 98.79%
$18 Change in substantial holding 3 Feb 2022 2:57PM $1.075 $0.013 fallen by 98.79%
$18 Opthea announces establishment of ATM Equity Program 2 Feb 2022 8:19AM $1.150 $0.013 fallen by 98.87%
$18 Form F-3 Registration Statement 2 Feb 2022 8:18AM $1.150 $0.013 fallen by 98.87%
$18 Becoming a substantial holder 31 Jan 2022 7:53PM $1.140 $0.013 fallen by 98.86%
$18 Ceasing to be a substantial holder 28 Jan 2022 2:46PM $1.135 $0.013 fallen by 98.85%
$18 Becoming a substantial holder 27 Jan 2022 8:17PM $1.180 $0.013 fallen by 98.90%
$18 Ceasing to be a substantial holder 25 Jan 2022 8:21PM $1.215 $0.013 fallen by 98.93%
$18 Opthea Receives A$6.6m R&D Tax Incentive 25 Jan 2022 8:32AM $1.225 $0.013 fallen by 98.94%
$18 Becoming a substantial holder 24 Jan 2022 8:14PM $1.225 $0.013 fallen by 98.94%
$18 Ceasing to be a substantial holder 17 Jan 2022 6:03PM $1.280 $0.013 fallen by 98.98%
$18 Change in substantial holding 17 Jan 2022 8:18AM $1.260 $0.013 fallen by 98.97%
$18 Becoming a substantial holder 14 Jan 2022 7:21PM $1.260 $0.013 fallen by 98.97%
$18 Opthea to present at H.C. Wainwright BIOCONNECT conference 5 Jan 2022 8:22AM $1.345 $0.013 fallen by 99.03%
$18 Opthea appoints CCO to lead Commercialization of OPT-302 4 Jan 2022 9:07AM $1.295 $0.013 fallen by 99%

351 - 375 of 733 results

Page 15 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.